Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS)
CNY 10.8
(-1.01%)
CNY 10.8
(-1.01%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 472.74 Million CNY | 154.93% |
| 2022 | 185.44 Million CNY | -44.16% |
| 2021 | 332.09 Million CNY | -23.88% |
| 2020 | 436.28 Million CNY | 6.76% |
| 2019 | 408.64 Million CNY | -11.63% |
| 2018 | 462.43 Million CNY | -11.22% |
| 2017 | 520.87 Million CNY | 2.22% |
| 2016 | 509.56 Million CNY | -12.94% |
| 2015 | 585.3 Million CNY | 22.63% |
| 2014 | 477.3 Million CNY | 9.25% |
| 2013 | 436.9 Million CNY | 12.13% |
| 2012 | 389.64 Million CNY | 31.61% |
| 2011 | 296.06 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 293.36 Million CNY | 9342.68% |
| 2024 Q2 | 99.96 Million CNY | -65.92% |
| 2024 Q3 | 4.4 Million CNY | -95.6% |
| 2023 Q1 | 236.59 Million CNY | 641.79% |
| 2023 Q4 | -3.17 Million CNY | -102.78% |
| 2023 Q3 | 114.09 Million CNY | 26.99% |
| 2023 Q2 | 89.84 Million CNY | -62.02% |
| 2023 FY | 472.74 Million CNY | 154.93% |
| 2022 Q4 | 31.89 Million CNY | 138.15% |
| 2022 Q2 | 81.17 Million CNY | -48.62% |
| 2022 Q3 | -83.61 Million CNY | -203.0% |
| 2022 FY | 185.44 Million CNY | -44.16% |
| 2022 Q1 | 157.98 Million CNY | 76.16% |
| 2021 Q1 | 155.31 Million CNY | -20.54% |
| 2021 Q3 | -33.85 Million CNY | -127.99% |
| 2021 Q4 | 89.68 Million CNY | 364.91% |
| 2021 FY | 332.09 Million CNY | -23.88% |
| 2021 Q2 | 120.96 Million CNY | -22.12% |
| 2020 Q2 | 57.86 Million CNY | -54.29% |
| 2020 Q4 | 195.46 Million CNY | 246.8% |
| 2020 Q1 | 126.59 Million CNY | 79.08% |
| 2020 Q3 | 56.36 Million CNY | -2.6% |
| 2020 FY | 436.28 Million CNY | 6.76% |
| 2019 FY | 408.64 Million CNY | -11.63% |
| 2019 Q1 | 168.88 Million CNY | 88.23% |
| 2019 Q2 | 67.98 Million CNY | -59.75% |
| 2019 Q4 | 70.68 Million CNY | -30.07% |
| 2019 Q3 | 101.09 Million CNY | 48.7% |
| 2018 FY | 462.43 Million CNY | -11.22% |
| 2018 Q4 | 89.72 Million CNY | -27.96% |
| 2018 Q3 | 124.54 Million CNY | 36.8% |
| 2018 Q2 | 91.04 Million CNY | -42.05% |
| 2018 Q1 | 157.12 Million CNY | -5.44% |
| 2017 Q1 | 117.39 Million CNY | -9.84% |
| 2017 FY | 520.87 Million CNY | 2.22% |
| 2017 Q4 | 166.16 Million CNY | 7.08% |
| 2017 Q3 | 155.18 Million CNY | 88.95% |
| 2017 Q2 | 82.12 Million CNY | -30.04% |
| 2016 FY | 509.56 Million CNY | -12.94% |
| 2016 Q4 | 130.21 Million CNY | -23.91% |
| 2016 Q3 | 171.14 Million CNY | 21.24% |
| 2016 Q2 | 141.15 Million CNY | 110.53% |
| 2016 Q1 | 67.04 Million CNY | -76.95% |
| 2015 Q1 | 27.6 Million CNY | -86.65% |
| 2015 Q2 | 211.75 Million CNY | 667.18% |
| 2015 FY | 585.3 Million CNY | 22.63% |
| 2015 Q4 | 290.82 Million CNY | 427.57% |
| 2015 Q3 | 55.12 Million CNY | -73.97% |
| 2014 Q3 | 50.1 Million CNY | -76.21% |
| 2014 FY | 477.3 Million CNY | 9.25% |
| 2014 Q4 | 206.79 Million CNY | 312.75% |
| 2014 Q2 | 210.59 Million CNY | 2045.71% |
| 2014 Q1 | 9.81 Million CNY | 0.0% |
| 2013 FY | 436.9 Million CNY | 12.13% |
| 2012 FY | 389.64 Million CNY | 31.61% |
| 2011 FY | 296.06 Million CNY | 0.0% |